This week, the bipartisan Disease X Act for pandemic preparedness was introduced in the US House of Representatives; Abiomed Impella pumps were the subject of a class I recall; Dasi Simulations and Endologix landed FDA clearances; and the FDA warned against the use of Getinge/Maquet Oxygenators.

J&J’s Q1 earnings announcement included challenges like the loss of exclusivity and competitive pressures, but the price renegotiation associated with the Inflation Reduction Act was not among them.

The leading global medtechs’ fiscal 2022 revenue reports are all in: Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished the year with strong quarters and Roche dropped a few places.

Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished 2022 with strong quarters, and Roche dropped a few places.